Blog

Khalis Mustafayev: Are BCR-ABL1 TKIs safe for cancer patients with chronic Hepatitis C?

Khalis Mustafayev/LinkedIn

Dec 1, 2024, 08:51

Khalis Mustafayev: Are BCR-ABL1 TKIs safe for cancer patients with chronic Hepatitis C?

KhalisMustafayev, Research Scientist at Miami Cancer Institute, shared on X:

“Are BCR::ABL1 TKIs safe for cancer patients with chronic Hepatitis C? Our latest study explores the virologic effect and hepatotoxicity of BCR::ABL1 TKIs.”

Virologic effect and hepatotoxicity of BCR::ABL1 tyrosine kinase inhibitors in cancer patients with chronic hepatitis C virus infection: A prospective study – ScienceDirect

Authors: Khalis Mustafayev, Eduardo Yepez Guevara, Courtney D. DiNardo, Elias Jabbour, Issa C. Ghayas, Ravin Ratan, Naveen Pemmaraju, Harrys A. Torres

cancer Courtney D. DiNardo Eduardo Yepez Guevara Elias Jabbour Harrys A. Torres hepatitis C Issa C. Ghayas Khalis Mustafayev Naveen Pemmaraju OncoDaily Oncology Ravin Ratan

100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2024: Part 10

OncoThon 2024 Raises $1.3 Million for Pediatric Cancer Research

Remembering Virgil Abloh: Louis Vuitton’s Creative Director Honored at 41 After His Brave Battle with Cardiac Angiosarcoma

Richard Sullivan: The State of Global Cancer Surgery from Political and Equity Perspectives

Immunotherapy for Bladder Cancer: Types, Success Rate, Side Effects & More

Special Coverage